Victoria, BC, May 8, 2024--Aurinia Pharmaceuticals Inc. issued its financial results for the first quarter ended March 31, 2024. Amounts are expressed in U.S. dollars. Total net revenue was $50.3 million for the three months ended March 31, 2024 and $34.4 million for the same period in 2023. representing growth of approximately 46%.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, February 22, 2024--Aurinia Pharmaceuticals Inc. provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company's strategic review.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, January 10, 2024--Aurinia Pharmaceuticals Inc. (Aurinia or the Company) provided an update on its 2023 fourth quarter and full year business performance.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, January 3, 2024--Aurinia Pharmaceuticals Inc. (Aurinia or the Company) - Aurinia announced the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, December 7, 2023--Aurinia Pharmaceuticals Inc. announced that the Company's collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin, a second-generation oral calcineurin inhibitor for the treatment of lupus nephritis (LN).
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, November 6, 2023--Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued its financial results for the three and nine months ended September 30, 2023. Amounts are expressed in U.S. dollars. The company reported net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, September 27, 2023--Aurinia Pharmaceuticals Inc. announced that its Board of Directors has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, August 28, 2023--Aurinia Pharmaceuticals Inc. announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the Company, bringing with them decades of combined leadership experience in the pharmaceutical and biotech industry.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, August 25, 2023---Aurinia Pharmaceuticals Inc. issued its financial results for the three and six months ended June 30, 2023.Q2 Net revenue up 47% YoY to $41.5 million US. Aurinia had cash, cash equivalents and restricted cash and short-term investments of $350.7 million as of June 30, 2023.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, July 24, 2023--Aurinia Pharmaceuticals Inc. announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the official peer-reviewed journal of the American College of Rheumatology.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need